文献速递治疗药物监测与药物基因组学特殊人群用药

开源最大后验贝叶斯给药软件AdDS助力万古霉素个体化治疗药物监测

Open-source maximum a posteriori-bayesian dosing AdDS to current therapeutic drug monitoring: Adapting to the era of individualized therapy.
PubMed 文献 · Pharmacotherapy · 2021-10-15

本研究开发了基于R的开源软件包AdDS,用于万古霉素等药物的最大后验贝叶斯给药,并利用健康与肥胖退伍军人数据比较完整重估计与贝叶斯更新先验的效果。结果显示重估计模型在多数受试者中预测相似或更优,基于患者特异清除率和最少采样的个体化方案有望改善治疗管理。

要点

  • AdDS为开源R软件包,支持万古霉素等药物的MAP贝叶斯给药临床实施。
  • 健康退伍军人中重估计模型使78.6%训练集和70.0%测试集预测相似或改善。
  • 肥胖退伍军人中重估计模型使81.8%训练集和85.7%测试集预测相似或改善。

核心结论

  • AdDS软件包可支持万古霉素MAP贝叶斯给药的临床实施,重估计模型参数在样本充足时优于贝叶斯更新先验。

研究设计与样本

  • 研究利用AdDS进行数据前后处理,比较完整重估计与贝叶斯更新先验在健康及肥胖退伍军人中的效果。
  • 健康退伍军人24例,训练集14例、测试集10例;肥胖退伍军人18例,训练集11例、测试集7例。

主要发现

  • 健康成人中,重估计模型使78.6%训练集和70.0%测试集受试者预测相似或改善。
  • 肥胖退伍军人中,重估计模型使81.8%训练集和85.7%测试集受试者预测相似或改善。
  • 重估计模型参数比贝叶斯更新先验在目标函数上带来更显著改善。

临床怎么用

  • 临床可利用AdDS基于患者特异清除率和最少采样生成个体化给药方案,尤其针对健康与肥胖人群的药代动力学差异。
  • 在样本和受试者充足时,可考虑重估计模型参数以优化万古霉素TDM。

局限性

  • 研究基于退伍军人医院的小样本数据,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent updates in the therapeutic drug monitoring (TDM) guidelines for vancomycin have rekindled interest in maximum a posteriori-Bayesian (MAP-Bayesian) estimation of patient-specific pharmacokinetic parameters. To create a versatile infrastructure for MAP-Bayesian dosing of vancomycin or other drugs, a freely available, R-based software package, Advanced Dosing Solutions (AdDS), was created to facilitate clinical implementation of these improved TDM methods. The objective of this study was to utilize AdDS for pre- and post-processing of data in order to streamline the therapeutic management of vancomycin in healthy and obese veterans. Patients from a local Veteran Affairs hospital were utilized to compare the process of full re-estimation versus Bayesian updating of priors on healthy adult and obese patient populations for use with AdDS. Twenty-four healthy veterans were utilized to train (14/24) and test (10/24) the base pharmacokinetic model of vancomycin while comparing the effects of updated and fully re-estimated priors. This process was repeated with a total of 18 obese veterans for both training (11/18) and testing (7/18). Comparison of MAP objective function between the original and re-estimated models for healthy adults indicated that 78.6% of the subjects in the training and 70.0% of the subjects in the testing datasets had similar or improved predictions by the re-estimated model. For obese veterans, 81.8% of subjects in the training dataset and 85.7% of subjects in the testing dataset had similar or improved predictions. Re-estimation of model parameters provided more significant improvements in objective function compared with Bayesian updating, which may be a useful strategy in cases where sufficient samples and subjects are available. The generation of bespoke regimens based on patient-specific clearance and minimal sampling may improve patient care by addressing fundamental pharmacokinetic differences in healthy and obese veteran populations.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Smith NM, Chan A, Wilkinson LA, et al. Open-source maximum a posteriori-bayesian dosing AdDS to current therapeutic drug monitoring: Adapting to the era of individualized therapy. Pharmacotherapy. 2021. PMID: 34618919. doi:10.1002/phar.2631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。